Skip to main content

Compare Stocks

Date Range: 

 InsmedLegend BiotechTurning Point TherapeuticsNektar TherapeuticsApellis Pharmaceuticals
SymbolNASDAQ:INSMNASDAQ:LEGNNASDAQ:TPTXNASDAQ:NKTRNASDAQ:APLS
Price Information
Current Price$26.23$29.60$69.35$18.98$44.26
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.21.31.71.51.6
Analysis Score3.53.53.53.03.4
Community Score2.52.33.13.02.7
Dividend Score0.00.00.00.00.0
Ownership Score0.00.01.71.71.7
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$53.57$49.00$153.71$25.00$130.08
% Upside from Price Target104.24% upside65.54% upside121.65% upside31.72% upside193.89% upside
Trade Information
Market Cap$2.64 billion$4.13 billion$3.36 billion$3.44 billion$3.67 billion
Beta2.43N/A1.231.761.47
Average Volume1,120,897375,689383,1941,171,247654,707
Sales & Book Value
Annual Revenue$136.47 million$64.39 millionN/A$114.62 millionN/A
Price / Sales19.8961.14N/A30.19N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.93 per shareN/A$11.28 per share$7.99 per share$0.46 per share
Price / Book8.95N/A2.38N/A
Profitability
Net Income$-254,340,000.00$-132,970,000.00$-72,130,000.00$-440,670,000.00$-304,710,000.00
EPS($3.01)N/A($2.99)($2.52)($4.64)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-145.14%-543.73%N/A-269.05%N/A
Return on Equity (ROE)-79.58%-205.60%-23.81%-30.74%-336.93%
Return on Assets (ROA)-31.14%-43.03%-23.08%-22.63%-78.28%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.03%N/AN/AN/A3.34%
Current Ratio7.95%4.88%35.45%8.25%9.86%
Quick Ratio7.43%4.87%35.45%8.15%9.86%
Ownership Information
Institutional Ownership PercentageN/A18.92%81.31%95.32%81.20%
Insider Ownership Percentage4.63%N/A23.20%2.99%9.50%
Miscellaneous
Employees373800142718374
Shares Outstanding103.49 million133.01 million49.16 million182.31 million80.50 million
Next Earnings Date8/5/2021 (Estimated)N/A8/9/2021 (Estimated)8/5/2021 (Estimated)7/30/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Apellis Pharmaceuticals (NASDAQ:APLS)  Shares Down 3% Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 3%
americanbankingnews.com - May 14 at 1:11 PM
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association ...Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association ...
apnews.com - May 12 at 1:11 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $39.00 at Credit Suisse GroupApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $39.00 at Credit Suisse Group
americanbankingnews.com - May 5 at 3:27 PM
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Are Reducing Their Forecasts For This YearApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Are Reducing Their Forecasts For This Year
finance.yahoo.com - May 4 at 7:45 AM
Histogen (NASDAQ:HSTO) versus Apellis Pharmaceuticals (NASDAQ:APLS) Financial ComparisonHistogen (NASDAQ:HSTO) versus Apellis Pharmaceuticals (NASDAQ:APLS) Financial Comparison
americanbankingnews.com - May 3 at 10:12 PM
Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) VP Sells 1,000 Shares of StockInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) VP Sells 1,000 Shares of Stock
americanbankingnews.com - May 3 at 8:18 PM
Q2 2021 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Raised by AnalystQ2 2021 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Raised by Analyst
americanbankingnews.com - May 3 at 2:48 AM
Zacks: Analysts Anticipate Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Will Post Earnings of -$1.80 Per ShareZacks: Analysts Anticipate Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Will Post Earnings of -$1.80 Per Share
americanbankingnews.com - May 1 at 10:16 AM
Is Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load?Is Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load?
finance.yahoo.com - May 1 at 9:37 AM
Apellis Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call PresentationApellis Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 30 at 4:50 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly  Earnings Results, Misses Estimates By $0.63 EPSApellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Misses Estimates By $0.63 EPS
americanbankingnews.com - April 29 at 3:20 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 5.1% on Analyst UpgradeApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 5.1% on Analyst Upgrade
americanbankingnews.com - April 29 at 2:28 PM
Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $39.00 at Credit Suisse GroupApellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $39.00 at Credit Suisse Group
americanbankingnews.com - April 29 at 1:02 PM
Apellis (APLS) Q1 Earnings Miss, Pegcetacoplan in FocusApellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
finance.yahoo.com - April 29 at 12:41 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Given New $39.00 Price Target at Credit Suisse GroupApellis Pharmaceuticals (NASDAQ:APLS) Given New $39.00 Price Target at Credit Suisse Group
marketbeat.com - April 29 at 12:24 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and Apellis Pharmaceuticals (APLS)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and Apellis Pharmaceuticals (APLS)
smarteranalyst.com - April 29 at 7:41 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 26 at 9:34 AM
Alec Machiels Sells 2,500 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockAlec Machiels Sells 2,500 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock
americanbankingnews.com - April 22 at 7:38 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Research Coverage Started at The Goldman Sachs GroupApellis Pharmaceuticals (NASDAQ:APLS) Research Coverage Started at The Goldman Sachs Group
americanbankingnews.com - April 22 at 8:32 AM
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
finance.yahoo.com - April 21 at 8:15 AM
Apellis to Showcase Leadership in Retina at Association for Research in Vision and ...Apellis to Showcase Leadership in Retina at Association for Research in Vision and ...
apnews.com - April 16 at 5:34 PM
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with ...Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with ...
apnews.com - April 13 at 1:02 PM
Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 27 at 12:32 PM
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating ...Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating ...
apnews.com - March 10 at 2:31 PM
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic AtrophyApellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
finance.yahoo.com - March 10 at 9:31 AM
Apellis stops COVID-19 program after missing mortality endpointApellis stops COVID-19 program after missing mortality endpoint
fiercebiotech.com - March 6 at 1:49 AM
DateCompanyBrokerageAction
5/10/2021InsmedMorgan StanleyLower Price Target
1/19/2021InsmedCredit Suisse GroupBoost Price Target
1/4/2021InsmedSVB LeerinkBoost Price Target
12/17/2020InsmedBerenberg BankInitiated Coverage
11/23/2020InsmedEvercore ISIReiterated Rating
10/12/2020InsmedStifel NicolausInitiated Coverage
6/25/2020InsmedHC WainwrightReiterated Rating
2/4/2020InsmedThe Goldman Sachs GroupBoost Price Target
1/15/2020InsmedJMP SecuritiesReiterated Rating
1/6/2020InsmedCowenReiterated Rating
1/2/2020InsmedCanaccord GenuityInitiated Coverage
1/20/2021Legend BiotechJPMorgan Chase & Co.Reiterated Rating
8/11/2020Legend BiotechJefferies Financial GroupReiterated Rating
4/6/2021Turning Point TherapeuticsRoth CapitalBoost Price Target
4/6/2021Turning Point TherapeuticsOppenheimerReiterated Rating
10/26/2020Turning Point TherapeuticsWells Fargo & CompanyBoost Price Target
5/7/2021Nektar TherapeuticsMizuhoReiterated Rating
3/1/2021Nektar TherapeuticsBenchmarkReiterated Rating
6/10/2020Nektar TherapeuticsCfraDowngrade
3/4/2020Nektar TherapeuticsBarclaysInitiated Coverage
2/28/2020Nektar TherapeuticsPiper SandlerReiterated Rating
2/28/2020Nektar TherapeuticsBTIG ResearchLower Price Target
2/28/2020Nektar TherapeuticsWilliam BlairReiterated Rating
1/8/2021Apellis PharmaceuticalsRaymond JamesBoost Price Target
12/1/2020Apellis PharmaceuticalsBMO Capital MarketsBoost Price Target
11/23/2020Apellis PharmaceuticalsSmith Barney CitigroupBoost Price Target
11/23/2020Apellis PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
11/19/2020Apellis PharmaceuticalsNeedham & Company LLCInitiated Coverage
10/9/2020Apellis PharmaceuticalsCantor FitzgeraldReiterated Rating
5/28/2020Apellis PharmaceuticalsUBS GroupInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.